Changchun High-tech, Anke Bio-Abandoned Growth Hormone Market Pattern or Changes

276 western medicines in 11 provinces in Guangdong Province, Changchun High-tech and Anke Biotech both abandoned the standard of water injection growth hormone
.
The two giants give up the in-hospital market, and the entire recombinant human growth hormone market pattern may change, which also brings reminders to the industry.
Under the environment of centralized procurement, product research and development innovation and early layout of varieties will be the long-term development of enterprises in the future.
The essential! On February 23, the Guangdong Provincial Drug Trading Center issued the "Notice on Viewing Information about Guangdong Alliance Diclofenac and Other Drugs Concentrated Procurement (First Batch) Registration Products", and disclosed two batches of registration products and price declaration products that meet the application conditions.
Regulatory information for enterprises to check and check
.
For the variety of recombinant human growth hormone that the industry is concerned about, the published information shows that 13 product specifications have been successfully declared
.
Among them, the companies applying for powder injection (human growth hormone for injection) include Anke Biology, Changchun Hi-tech subsidiary Jinsai Pharmaceutical, Zhongshan Weiming Haiji, and Shanghai United Saier; Recombinant Human Growth Hormone Injection) was only declared by the multinational company Novo Nordisk, and Changchun High-tech and Anke Bio both abandoned the bid
.
Previously, on February 22, Changchun High-tech released an investor relations activity exchange form that revealed that as of the registration deadline for Guangdong Alliance's centralized drug procurement, the recombinant human growth hormone aqueous solution of its subsidiary Jinsai Pharmaceuticals has not been declared
.
As soon as the news came out, Changchun Hi-Tech rose rapidly in the intraday market, with an increase of more than 2% within 5 minutes, and an intraday increase of 7.
52%
.
As of the close, Changchun High-tech reported 184.
05, up 5.
16%
.
Changchun Hi-Tech and Anke Bio have abandoned the bid, and the growth hormone market structure or biotransformation growth hormone is a protein hormone secreted by eosinophilic granulosa cells in the anterior pituitary gland
.
At present, the vast majority of recombinant human growth hormone indications are mainly aimed at children with slow growth, and only individual product indications include the use of adults or the elderly
.
Growth hormone can be divided into three dosage forms: powder injection, water injection and long-acting water injection
.
Among them, water injection is currently the mainstream dosage form in China, with a market share of about 60%; powder injection accounts for about 38%, and long-acting dosage form is only 1%
.
In terms of price, long-acting water injection is the most expensive, with an annual treatment cost of more than 200,000 yuan; powder injection and water injection are about 25,000 yuan/year and 50,000 yuan/year respectively
.
From the perspective of market share, in the field of powder injection, Anke Biology ranks first, accounting for 44% of the market share, while United Cyclone and Kinsey Pharmaceutical occupy 31% and 16% of the market share respectively
.
In the field of water injection, Jinsai Pharmaceutical almost exclusively owns this market, accounting for as much as 70% of its revenue
.
Anke Bio launched water injection in 2019, but due to the epidemic, there was no heavy volume in 2020
.
Since the price of water injection is twice that of powder injection and the profit is higher, this field is the focus of competition among enterprises
.
This time, the Guangdong 11-province coalition grouped water injection and powder injection into one group.
For example, the highest effective declaration price of powder injection of 16IU specification is 182.
36 yuan, while the water injection of 15IU/5mg/3ml specification has the highest effective declaration price.
The price is 173.
57 yuan, and the prices of some water injections and powder injections have been pulled to the same level
.
According to the quotation rules, if the powder injection enterprises reduce the price by 10-19%, they are expected to obtain 25%-70% of the pre-purchased volume in the first year
.
For water injection products, it may be necessary to reduce the price by more than 50% to obtain the same market
.
According to public data, water injection is the core source of income of Jinsai Pharmaceutical
.
In Jinsai Pharmaceutical's revenue, sales of water injection account for about 70%-80%, powder injection accounts for 8%-9%, and long-term effect accounts for about 12%-13%
.
If Jinsai Shuizhen participates in this bidding, it means that the price will be reduced by about 50% in order to obtain the relevant hospital market, which will undoubtedly bring a great impact on Jinsai's profits
.
It may be a more reasonable way to give up water injection products and maintain market share by reducing the price of powder injections
.
In addition, according to the Southern Metropolis Daily, Jinsai Pharmaceutical has a very unique sales model, which mainly relies on recruiting new patients in the top three public hospitals.
etc.
, and has a very strong ability to control the terminals of the "outside the hospital market"
.
It is reported that "nearly 70% of the sales of Jinsai Pharmaceuticals come from the 'off-hospital market'
.
" Therefore, it may not be impossible for Kinsai Pharmaceuticals to keep the profits of water injection and move to the out-of-hospital market
.
For Anke Biology, its growth hormone powder injection products are currently in a relatively monopolized position in the market, with higher gross profit and larger scale, while the current market size of water injection is small, and the company's profit from entering centralized procurement There is no obvious benefit, so it is understandable not to participate in the competition in the water injection market
.
Although this time is only an alliance of 11 provinces, but according to the current trend of price linkage in various provinces, this centralized procurement price system is likely to continue to the whole country and affect the entire price system.
Therefore, for enterprises, it is not too much to consider many factors before lowering the price.

.
In addition, this time, the price of powder injection and water injection will be brought to a unified level, and patients are definitely more willing to use the more advanced water injection, which means that the market for powder injection will be transferred, and the entire market will be transferred.
The pattern of the drug market will also be changed, and there are concerns for companies that have two specifications at the same time
.
According to the Southern Metropolis Daily, insiders analyzed that neither of the two companies declared for centralized procurement this time, and the water needle has completely become a product sold in the out-of-hospital market.
bonus
.
Although the competition in the out-of-hospital market will also bring about gradual price reductions, it is obviously much milder than centralized procurement
.
This is an optimal situation for both of them
.
Nowadays, centralized procurement is normalized and should be collected as much as possible.
The depth and breadth continue to exceed expectations, and it has become the trump card for changing the investment in the pharmaceutical industry.
Enterprises with a single track face huge operational risks
.
This time, Changchun Hi-Tech and Anke Bio's abandonment of the bid sounded the alarm to the industry and also brought a reminder that product research and development innovation and early layout of varieties will be the key to the long-term development of enterprises in the future!